Literature DB >> 32540218

Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.

Adam B Weiner1, Farzana A Faisal2, Elai Davicioni3, R Jeffrey Karnes4, Donald J Vander Griend5, Tamara L Lotan6, Edward M Schaeffer7.   

Abstract

BACKGROUND: Homeobox B13 (HOXB13) expression regulates normal prostate development and mutations are associated with prostate cancer (PCa) formation.
OBJECTIVE: To assess the role of HOXB13 mRNA expression in PCa progression following radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: Genome-wide expression profiles were queried from two retrospective prostatectomy cohorts with follow-up data (Mayo Clinic, n=780; Johns Hopkins Medical Institute [JHMI], n=355), and a prospective genomic registry (n=5239). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regressions were used to analyze metastasis-free survival (MFS). RESULTS AND LIMITATIONS: HOXB13 expression in primary PCa increased with increasing tumor grade and with high metastatic potential based on a genomic signature. The highest quartile of HOXB13 expression was associated with worse MFS compared with the lowest quartile (Mayo Clinic: adjusted hazard ratio [AHR] 1.46, 95% confidence interval [CI] 1.03-2.06, and JHMI: AHR 1.80, 95% CI 1.02-3.19). The combinations of high HOXB13 expression and low expression of its binding partner, MEIS1 (AHR 2.03, 95% CI 1.54-2.66) or MEIS2 (AHR 1.73, 95% CI 1.33-2.26), portended worse MFS. Additionally, high HOXB13 expression in combination with low MEIS1/2 expression correlated with high expression of androgen receptor-mediated genes. The retrospective nature of this study subjects the findings to a bias due to unmeasured variables.
CONCLUSIONS: Primary PCa tumors with increased HOXB13 expression have an increased propensity for metastases following prostatectomy, particularly in the setting of low MEIS1/2 expression. High androgen receptor output may account for worse outcomes for these tumors and suggests heightened sensitivity to androgen suppression. PATIENT
SUMMARY: Using genomic data from a large number of prostate cancer (PCa) tumors, we found that increased expression of homeobox B13 (HOXB13), a gene related to normal prostate development, was associated with worse outcomes following surgery for PCa. A biomarker signature suggests that these tumors would be more susceptible to androgen suppression, a common treatment for PCa. Take Home  Messagece:: In multiple large cohorts, prostate cancer tumors with high homeobox B13 (HOXB13) expression and low expression of its binding partner MEIS1/2 were enriched with high androgen receptor output and had an increased propensity for metastases following surgery.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disease progression; Homeobox B13; Homeodomain proteins; Prostatic neoplasms

Mesh:

Substances:

Year:  2020        PMID: 32540218      PMCID: PMC7736205          DOI: 10.1016/j.euo.2020.05.001

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  22 in total

1.  MEIS1 functions as a potential AR negative regulator.

Authors:  Liang Cui; Mingyang Li; Fan Feng; Yutao Yang; Xingyi Hang; Jiajun Cui; Jiangping Gao
Journal:  Exp Cell Res       Date:  2014-08-23       Impact factor: 3.905

2.  HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.

Authors:  Dorhyun Johng; Gonzalo Torga; Charles M Ewing; Kideok Jin; John D Norris; Donald P McDonnell; William B Isaacs
Journal:  Prostate       Date:  2018-12-17       Impact factor: 4.104

3.  The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Authors:  Matthew R Cooperberg; Peter R Carroll; Marc A Dall'Era; Benjamin J Davies; John W Davis; Scott E Eggener; Felix Y Feng; Daniel W Lin; Todd M Morgan; Alicia K Morgans; Daniel E Spratt; Samir S Taneja; David F Penson
Journal:  Eur Urol       Date:  2019-05-23       Impact factor: 20.096

4.  GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.

Authors:  Renu Jeyapala; Andrea J Savio; Ekaterina Olkhov-Mitsel; Shivani Kamdar; Fang Zhao; Carmelle Cuizon; Richard S C Liu; Alex Zlotta; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  Eur Urol Oncol       Date:  2018-09-01

5.  Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.

Authors:  Anis A Hamid; Kathryn P Gray; Ying Huang; Michaela Bowden; Mark Pomerantz; Massimo Loda; Christopher J Sweeney
Journal:  Eur Urol Oncol       Date:  2018-10-04

6.  Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.

Authors:  Daniel E Spratt; Mohammed Alshalalfa; Nick Fishbane; Adam B Weiner; Rohit Mehra; Brandon A Mahal; Jonathan Lehrer; Yang Liu; Shuang G Zhao; Corey Speers; Todd M Morgan; Adam P Dicker; Stephen J Freedland; R Jeffery Karnes; Sheila Weinmann; Elai Davicioni; Ashley E Ross; Robert B Den; Paul L Nguyen; Felix Y Feng; Tamara L Lotan; Arul M Chinnaiyan; Edward M Schaeffer
Journal:  Clin Cancer Res       Date:  2019-09-12       Impact factor: 12.531

7.  HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

Authors:  Maurice P H M Jansen; Anieta M Sieuwerts; Maxime P Look; Kirsten Ritstier; Marion E Meijer-van Gelder; Iris L van Staveren; Jan G M Klijn; John A Foekens; Els M J J Berns
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

Review 8.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Authors:  Daniel E Spratt; Kasra Yousefi; Samineh Deheshi; Ashley E Ross; Robert B Den; Edward M Schaeffer; Bruce J Trock; Jingbin Zhang; Andrew G Glass; Adam P Dicker; Firas Abdollah; Shuang G Zhao; Lucia L C Lam; Marguerite du Plessis; Voleak Choeurng; Zaid Haddad; Christine Buerki; Elai Davicioni; Sheila Weinmann; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Felix Y Feng
Journal:  J Clin Oncol       Date:  2017-03-30       Impact factor: 44.544

9.  Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer.

Authors:  Yawei Zhao; Tsuyoshi Yamashita; Mutsuo Ishikawa
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

10.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.

Authors:  Mark M Pomerantz; Fugen Li; David Y Takeda; Romina Lenci; Apurva Chonkar; Matthew Chabot; Paloma Cejas; Francisca Vazquez; Jennifer Cook; Ramesh A Shivdasani; Michaela Bowden; Rosina Lis; William C Hahn; Philip W Kantoff; Myles Brown; Massimo Loda; Henry W Long; Matthew L Freedman
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

View more
  5 in total

1.  Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.

Authors:  Duy T Nguyen; Wei Yang; Kiran Mahajan; Arun Renganathan; Cody Weimholt; Duminduni H Angappulige; Thanh Nguyen; Robert W Sprung; Gerald L Andriole; Eric H Kim; Nupam P Mahajan
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

Review 2.  Genomic biomarkers to guide precision radiotherapy in prostate cancer.

Authors:  Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran
Journal:  Prostate       Date:  2022-08       Impact factor: 4.012

3.  Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression.

Authors:  Siyuan Cheng; Shu Yang; Yingli Shi; Runhua Shi; Yunshin Yeh; Xiuping Yu
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

4.  Role of IGF2 in the Study of Development and Evolution of Prostate Cancer.

Authors:  P Porras-Quesada; J M González-Cabezuelo; V Sánchez-Conde; I Puche-Sanz; V Arenas-Rodríguez; C García-López; J F Flores-Martín; J M Molina-Hernández; M J Álvarez-Cubero; L J Martínez-González; F Vázquez-Alonso
Journal:  Front Genet       Date:  2022-01-04       Impact factor: 4.599

5.  HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.

Authors:  Andrei Daniel Timofte; Simona Eliza Giuşcă; Ludmila Lozneanu; Mariana Bianca Manole; Iulian Prutianu; Bogdan Gafton; Andreea Rusu; Irina Draga Căruntu
Journal:  Rom J Morphol Embryol       Date:  2021 Jan-Mar       Impact factor: 1.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.